ESI gets rights to diabetes technology
Thursday, 19 December, 2002
Singapore-based stem cell company ES Cell International (ESI) has acquired patent rights to technology relating to the transformation of stem cells into insulin-producing cells from US company Curis.
Under the terms of the agreement, ESI will be responsible for continuing the development and testing of Curis' diabetes stem cell technologies.
According to Robert Klupacs, CEO of ESI, the acquisition will enhance ESI's diabetes cell therapy program and complements other technology the company has licensed in for the program.
"Accessing both Curis' world-class technologies and research capabilities will significantly accelerate our ability to bring cell-based therapies for diabetes to the clinic," Klupacs said in a statement.
ESI is developing therapeutic technologies for the treatment of diabetes and Parkinson's disease using embryonic and adult stem cells.
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
